Tom 19, Nr 3 (2023)
Artykuł przeglądowy
Opublikowany online: 2023-10-04
Wyświetlenia strony 411
Wyświetlenia/pobrania artykułu 299
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Możliwości farmakoterapii padaczki lekoopornej

Elżbieta Szczygiel-Pilut12
Pol. Przegl. Neurol 2023;19(3):216-222.

Streszczenie

Padaczka jest przewlekłym schorzeniem neurologicznym dotykającym pacjentów we wszystkich grupach wiekowych. Standardem postępowania w leczeniu choroby pozostaje doustna farmakoterapia. W ostatnich dziesięcioleciach opracowano wiele leków przeciwpadaczkowych, do których należy brywaracetam. Lek ten wydaje się obiecującym wyborem, zwłaszcza u pacjentów z lekooporną postacią choroby. W pracy przedstawiono charakterystykę i ocenę korzyści stosowania brywaracetamu u pacjentów ze źle kontrolowaną padaczką w porównaniu z lewetyracetamem i innymi lekami przeciwpadaczkowymi III generacji.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Gayke M, Narode H, Eppa G, et al. Synthetic approaches toward the synthesis of brivaracetam: an antiepileptic drug. ACS Omega. 2022; 7(3): 2486–2503.
  2. Sills GJ, Rogawski MA. Mechanisms of action of currently used antiseizure drugs. Neuropharmacology. 2020; 168: 107966.
  3. Zaccara G. Brivaracetam: new compound approved for the treatment of epilepsy. Drugs Today (Barc). 2016; 52(4): 219–227.
  4. Briviact Charakterystyka Produktu Leczniczego. https://www.ucb.pl/produkty/lista-lekow/Briviact (February 9, 2023).
  5. Rosenstiel P. Brivaracetam (UCB 34714). Neurotherapeutics. 2007; 4(1): 84–87.
  6. Markham A. Brivaracetam: first global approval. Drugs. 2016; 76(4): 517–522.
  7. Klein P, Tyrlikova I, Brazdil M, et al. Brivaracetam for the treatment of epilepsy. Expert Opin Pharmacother. 2016; 17(2): 283–295.
  8. Niespodziany I, André VM, Leclère N, et al. Brivaracetam differentially affects voltage-gated sodium currents without impairing sustained repetitive firing in neurons. CNS Neurosci Ther. 2015; 21(3): 241–251.
  9. Niespodziany I, Rigo JM, Moonen G, et al. Brivaracetam does not modulate ionotropic channels activated by glutamate, γ-aminobutyric acid, and glycine in hippocampal neurons. Epilepsia. 2017; 58(11): e157–e161.
  10. Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos. 2016; 44(6): 792–799.
  11. Moseley BD, Chanteux H, Nicolas JM, et al. A review of the drug-drug interactions of the antiepileptic drug brivaracetam. Epilepsy Res. 2020; 163: 106327.
  12. Kruithof AC, Watanabe S, Peeters PAm, et al. Pharmacological interactions between brivaracetam and ethanol in healthy males. J Psychopharmacol. 2017; 31(7): 915–926.
  13. Toledo M, Whitesides J, Schiemann J, et al. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016; 57(7): 1139–1151.
  14. Lattanzi S, Canafoglia L, Canevini MP, et al. BRIVAFIRST Group Membership. Brivaracetam in older patients with focal seizures: evidence from the BRIVAracetam add on First Italian netwoRk Study (BRIVAFIRST). Drugs Aging. 2022; 39(4): 297–304.
  15. Hansen CC, Ljung H, Brodtkorb E, et al. Mechanisms underlying aggressive behavior induced by antiepileptic drugs: focus on topiramate, levetiracetam and perampanel. Behav Neurol. 2018; 2018: 2064027.
  16. Löscher W, Gillard M, Sands ZA, et al. Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond. CNS Drugs. 2016; 30(11): 1055–1077.
  17. Steinhoff BJ, Klein P, Klitgaard H, et al. Behavioral adverse events with brivaracetam, levetiracetam, perampanel, and topiramate: a systematic review. Epilepsy Behav. 2021; 118: 107939.
  18. Tomson T, Battino D, Bromley R, et al. Breastfeeding while on treatment with antiseizure medications: a systematic review from the ILAE Women Task Force. Epileptic Disord. 2022; 24(6): 1020–1032.
  19. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia. 2015; 56(12): 1890–1898.
  20. Brigo F, Bragazzi NL, Nardone R, et al. Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs. Seizure. 2016; 42: 29–37.
  21. Väätäinen S, Soini E, Peltola J, et al. Economic value of adjunctive brivaracetam treatment strategy for focal onset seizures in Finland. Adv Ther. 2020; 37(1): 477–500.
  22. Villanueva V, Serratosa JM, Toledo M, et al. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain. Epilepsy Behav. 2023; 139: 109054.
  23. Ángel Calleja M, Navarro A, Serratosa JM, et al. Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022; 22(7): 1127–1136.
  24. Laskier V, Agyei-Kyeremateng KK, Eddy AE, et al. Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia. 2023; 64(4): 843–856.
  25. Privitera M, Richy FF, Schabert VF. Indirect treatment comparison of cenobamate to other ASMs for the treatment of uncontrolled focal seizures. Epilepsy Behav. 2022; 126: 108429.
  26. Lattanzi S, Trinka E, Zaccara G, et al. Third-generation antiseizure medications for adjunctive treatment of focal-onset seizures in adults: a systematic review and network meta-analysis. Drugs. 2022; 82(2): 199–218.
  27. Cutillo G, Tolba H, Hirsch LJ. Anti-seizure medications and efficacy against focal to bilateral tonic-clonic seizures: A systematic review with relevance for SUDEP prevention. Epilepsy Behav. 2021; 117: 107815.
  28. Leach J, Kelemen A, Doherty C, et al. Impact of number of life time antiseizure medications on 12-month effectiveness, quality of life and tolerability outcomes of adjunctive brivaracetam in patients with focal seizures: Post- hoc analysis of a real-world European study. P-309. Geneva, Switzerland, 14th European Epilepsy Congress, 9–13 July 2022.
  29. Hu TY, Wang HQ, Zhang WP, et al. Network meta-analysis of antiepileptic drugs in focal drug-resistant epilepsy. Epilepsy Res. 2020; 167: 106433.